Saturday, December 3, 2022


Biotechnology News Magazine

TECHKON Offers E-Health Technology Patent for Smartphone based Medical Rapid Test

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

TECHKON GmbH, a global leader in color measurement and spectrophotometric solutions, has invented a simple-to-use and effective device and method to analyze body fluids and determine medical parameters and diagnoses instantly.

Depending on the type of medical parameter to be analyzed, the user puts a drop of saliva, blood, or any other body fluid on a card that contains a bio-/ chemical reaction substance and separation mechanism.

The medical rapid test result is displayed on the card or its backside as a change in color or geometric pattern and put into context with a numerical or graphical description. It can be analyzed visually and by using the camera and processing unit of a digital mobile device such as a smartphone.

In the case of a blood sample, the card can contain a perforating-/ needle- or cutting mechanism to extract blood, for example from the fingertip. The card can additionally have a temperature, a personal identity, memory, and/or data processing and transmission module and it can be part of a sterile packaging/disposal unit.

The method can be used for single- or multiple applications and also for consecutive tests for trend evaluation.
The contents of the patent EP3272285B1 can be viewed at

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine